PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Revenue keeps expanding sharply, but two consecutive quarters of operating losses highlight the gap between top-line growth and profitability recovery.
2025 consolidated revenue reached KRW170.1bn, roughly 11.6x the 2022 level, but owners' net income swung to a loss
The company's registered industry classification itself shifted from OLED equipment to pharmaceutical manufacturing after merging with Korea Global Pharm
Subsidiaries Bigthink Therapeutics (oncology distribution) and Battery Solutions (spent-battery recycling) are jointly driving top-line growth
Pipeline milestones are progressing step by step, including a Phase 2 IND filing for ovarian cancer candidate Idetrexed and an international patent filing for oral peptide platform Oraloid
The debt ratio climbed every year from 63.7% in 2022 to 187.0% in 2025, and operating cash flow also turned negative in 2025
KIPS Pharma started out in 2000 as an OLED equipment maker and transformed its business structure into a pharma-and-bio-centered company through the absorption merger with Korea Global Pharm and a series of biotech acquisitions completed in 2024-2025.
Once pharmaceutical manufacturing revenue exceeded 90 percent of the first-half 2025 total, the company's official industry classification itself was changed from special-purpose machinery manufacturing to pharmaceutical manufacturing.
The current business structure is broadly split into three segments: pharma/bio, spent-battery recycling (via subsidiary Battery Solutions), and a remaining legacy OLED equipment operation.
In the first half of 2026, pharma/bio segment revenue reached KRW41.8bn, sharply up from KRW24.1bn a year earlier, while Battery Solutions grew 53 percent to KRW91.1bn.
The pharma segment combines the parent's prescription drug manufacturing and sales, subsidiary Bigthink Therapeutics' oncology drug distribution, Algok Bio's new-drug pipeline, and KIPS Biomed's oral drug-delivery platform.
Bigthink is expanding sales to tertiary hospitals through its own products such as breast cancer treatment Neolins and five oncology drugs secured via an exclusive distribution deal with Handok Teva, with the contracted products accounting for 18 percent of Bigthink's total first-half 2026 revenue.
Battery Solutions is a spent-battery recycling specialist producing pure and alloy lead ingots, and it expanded annual capacity from about 36,000 tons to over 70,000 tons through rotary-furnace expansion.
According to a Seoul Pyeongga Information report commissioned by the Korea IR Council, the pharma/bio segment accounted for 28.9 percent of total 2025 revenue.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩43.3B | -₩1B | −2.3% |
| 2025Q3 | ₩40.9B | ₩1.4B | 3.5% |
| 2025Q4 | ₩45.2B | ₩1B | 2.2% |
| 2026Q1 | ₩59.4B | -₩700M | −1.1% |
| 2026Q2 | ₩74.9B | -₩2.4B | −3.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩14.6B | -₩8.6B | -₩11.4B | −58.9% | −21.4% | 63.7% |
| 2023 | ₩92.1B | ₩3.1B | ₩3.9B | 3.3% | 6.9% | 100.2% |
| 2024 | ₩127.6B | ₩6.2B | ₩1.1B | 4.9% | 2.2% | 161.3% |
| 2025 | ₩170.1B | ₩1.6B | -₩9.8B | 0.9% | −15.8% | 187.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue in 2025 reached KRW170.1bn, extending a clear growth trajectory from KRW127.6bn in 2024, KRW92.1bn in 2023, and KRW14.6bn in 2022.
Operating profit, however, was only KRW1.57bn in 2025 (a 0.9 percent margin), actually lower than the KRW6.22bn (4.9 percent) recorded in 2024, showing that margins have drifted lower again after the company exited the KRW8.61bn operating loss of 2022.
Owners' net income swung back to a loss of KRW9.79bn in 2025 from a profit of KRW1.11bn in 2024, and combined with KRW3.93bn in 2023 and a loss of KRW11.38bn in 2022, annual bottom-line results have been notably volatile.
On a quarterly basis, revenue rose steadily from KRW43.3bn in 2025Q2 to KRW40.9bn in 2025Q3, KRW45.2bn in 2025Q4, KRW59.4bn in 2026Q1, and KRW74.9bn in 2026Q2.
Operating results, however, turned positive in 2025Q3 (+KRW1.45bn) and 2025Q4 (+KRW1.01bn) before swinging back to losses in 2026Q1 (-KRW0.66bn) and 2026Q2 (-KRW2.40bn).
Owners' net income showed even wider swings, from a large loss of KRW8.79bn in 2025Q4 to a large gain of KRW5.67bn in 2026Q1 and back to a loss of KRW8.81bn in 2026Q2, a pattern that diverges from the operating-line trend and suggests meaningful non-operating items were at play.
Management has attributed the first-half operating loss to temporary factors including higher R&D spending from pipeline in-licensing and expanded research headcount as well as concentrated marketing outlays, and has pointed to the possibility of an earnings turnaround within the year as revenue continues to grow.
The debt ratio rose every year from 63.7 percent in 2022 to 100.2 percent in 2023, 161.3 percent in 2024, and 187.0 percent in 2025, while operating cash flow also turned negative to KRW-14.92bn in 2025 from KRW4.81bn in 2024, indicating that top-line expansion has been accompanied by growing financial leverage.
The pharma/bio segment KIPS Pharma operates in is generally classified as a small-to-mid-cap group of companies holding diversified pipelines spanning oncology drugs, rare-disease treatments, and oral peptide drug-delivery platforms.
In the FRα (folate receptor alpha)-targeted oncology field, interest in new mechanisms of action has grown as existing antibody-drug conjugate agents have faced side-effect issues such as ocular toxicity.
The oral insulin and GLP-1 peptide-delivery platform space is an area where numerous biotechs are competing technologically to improve medication compliance in a market still dominated by injectable therapies.
The spent-battery recycling segment is an industry growing on rising demand for end-of-life electric-vehicle battery processing, and subsidiary Battery Solutions surpassed KRW100bn in annual revenue for the first time in 2024, earning designation as a "venture company surpassing KRW100bn in sales." That said, the recycling industry is capital-intensive, with raw-material price swings in nickel, cobalt, and lithium as well as heavy capital expenditure directly affecting results.
In oncology drug distribution, small-to-mid-sized distributors with access to tertiary hospital channels are competing to expand their portfolios through exclusive sales agreements with multinational pharmaceutical companies, and an industry source noted that improving sales efficiency by adding new products to existing sales networks is key.
The company disclosed first-half 2026 consolidated revenue of KRW134.3bn, up 60 percent year over year, according to a report dated September 4, 2026 — a preliminary data point beyond this report's confirmed financial window through 2026Q2.
CEO Kim Ha-yong stated that the company aims to reach KRW500bn in consolidated revenue by the end of 2027 through additional M&A and business expansion.
Among the pipeline candidates, ovarian cancer treatment Idetrexed had its Phase 2 clinical trial plan filed with Korea's Ministry of Food and Drug Safety in March 2026, and the company said it plans to begin a standalone Phase 2 trial in Korea and Europe during the second half of 2026.
The company also said a Phase 1b/2a combination trial with olaparib led by the UK's Institute of Cancer Research is progressing smoothly.
Oral drug-delivery platform Oraloid completed an international PCT patent filing in August 2026, and the company said partnering discussions with global pharmaceutical companies are ongoing.
Subsidiary Bigthink Therapeutics, whose first-half revenue already exceeded last year's full-year total, has set a target of surpassing KRW10bn in annual revenue for 2026.
Battery Solutions expects the capacity expansion from its completed rotary-furnace project to continue contributing to production in the second half of the year.
Owners' net income has remained in the red even over the most recent four quarters, suggesting the market's valuation of the company likely reflects expectations around the pharma/bio transformation and pipeline progress more than current profitability.
The price-to-book ratio trades in a range that carries a premium over net asset value, which can be interpreted as reflecting the multiple drug pipelines and growth prospects of its subsidiaries. The company has not yet paid a dividend, so its appeal on a dividend-yield basis remains limited.
Annual results show notable swings in profitability — from a profit in 2023 to a smaller profit in 2024 and back to a loss in 2025 — meaning the stability of any valuation is likely to hinge on whether profitability recovers and pipeline milestones are confirmed going forward.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Consolidated revenue grew rapidly from KRW14.6bn in 2022 to KRW170.1bn in 2025, and continued expanding in the first half of 2026 to KRW134.3bn, up 60 percent year over year.
Multiple subsidiaries including Bigthink and Battery Solutions are expanding simultaneously, so growth drivers are not concentrated in a single business.
New-drug development is progressing sequentially, including the domestic Phase 2 IND filing for Idetrexed and the international patent filing for Oraloid.
External collaborations are also expanding, including a combination trial led by the UK Institute of Cancer Research and joint research on a PTH treatment with Daewoong Pharmaceutical.
The company's portfolio spans two unrelated industries — pharma/bio and battery recycling — so weakness in one segment can potentially be offset by the other. Battery Solutions has already completed its facility expansion, raising recycling segment production capacity.
Despite revenue growth, the 2025 operating margin fell to 0.9 percent from 4.9 percent in 2024, and the company posted operating losses in both the first and second quarters of 2026. Owners' net income also turned to a loss in 2025 and has shown large quarterly swings since.
The debt ratio rose every year from 63.7 percent in 2022 to 187.0 percent in 2025, and operating cash flow also turned negative to KRW-14.9bn in 2025. While revenue has expanded through a series of acquisitions, the associated funding burden has grown alongside it.
Idetrexed is only at the Phase 2 stage and Oraloid remains at the patent and preclinical stage, meaning commercialization could require substantial additional time and cost. Global partnering discussions are ongoing, but no finalized agreement has been confirmed yet.
If clinical results for pipeline candidates fall short of expectations or timelines slip, the valuation attributed to the pipeline could decline. Oral delivery platform technologies such as Oraloid have no commercialized precedent yet, leaving technical uncertainty.
If the rising debt ratio and deteriorating operating cash flow continue, additional borrowing or equity funding could become necessary. Non-controlling interests represent a substantial portion of total equity, contributing to large swings in income attributable to owners.
The transition from OLED equipment to pharma/bio and battery recycling is still underway, and integrating and realizing synergies among the multiple acquired subsidiaries may take time. Whether management's stated goal of KRW500bn in 2027 revenue is achieved will also require ongoing verification.
Watch for any additional nonclinical or clinical data disclosures on the oral insulin platform at conferences such as the EASD annual meeting, and for progress in global partnering discussions.
A key point to check whether the standalone Phase 2 trial for Idetrexed actually begins in Korea and Europe, and how initial enrollment progresses.
The Q3 quarterly report should reveal whether operating results return to profit and whether the debt ratio and operating cash flow show improvement.
Watch for whether the additional M&A deals mentioned by management materialize and how much of Battery Solutions' expanded production capacity translates into actual revenue.
KIPS Pharma has rapidly transformed from an OLED equipment maker into an integrated healthcare company spanning pharma/bio and battery recycling, expanding revenue sharply each year.
Yet contrary to top-line growth, the 2025 operating margin declined, operating losses were posted in both the first and second quarters of 2026, and the debt ratio rose while operating cash flow turned negative at the same time.
Pipeline candidates such as Idetrexed and Oraloid are advancing step by step both domestically and abroad, but most remain at early clinical or preclinical stages.
While subsidiaries Bigthink and Battery Solutions show clear individual growth, translating their performance into a sustained profitability recovery at the consolidated level may take time.
Investors will want to monitor upcoming quarterly results for the durability of any return to operating profit, management of financial leverage, and confirmation of actual clinical pipeline milestones.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.